Tranexamic Acid Composition for Adhesion Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for adhesions and ileus, particularly post-operative ileus, are ineffective, leading to significant morbidity, prolonged hospital stays, and increased healthcare costs, with no broadly effective interventions available.
Innovation Solution
An aqueous pharmaceutical composition comprising tranexamic acid, polyethylene glycol, and at least one electrolyte, administered orally prior to a surgical procedure, to prevent and treat adhesions and ileus by reducing their incidence, severity, and formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If no preventive treatment is administered, then the surgical procedure can be performed without additional intervention, but adhesions and ileus will form causing prolonged hospitalization and increased morbidity
Solution Approach 1:
The patent applies preliminary action by administering the pharmaceutical composition containing tranexamic acid, polyethylene glycol, and electrolytes before the surgical procedure to prevent adhesion formation and ileus. This pre-treatment approach addresses the contradiction by preparing the patient's system in advance to resist the harmful effects of surgery, thereby reducing post-operative complications and hospital stay duration without interfering with the surgical procedure itself.
2Ease of operation
If supportive measures alone are used for ileus treatment, then the treatment approach remains simple, but patient mobility and recovery are significantly delayed
Solution Approach 1:
The patent applies parameter changes by modifying the chemical composition parameters of the gastrointestinal environment through administration of a specific pharmaceutical formulation. The composition includes tranexamic acid (0.1-5.0 wt%), polyethylene glycol (0.1-10.0 wt%), glucose (0.01-25.0 wt%), and electrolytes (0.001-10 wt%), which together create optimal conditions for preventing adhesions and accelerating ileus resolution, thereby improving recovery speed while maintaining treatment simplicity.
3Reliability
If tranexamic acid is administered alone, then the treatment targets fibrin matrix degradation, but overall gastrointestinal function recovery is insufficient
Solution Approach 1:
The patent applies composite materials by combining tranexamic acid with polyethylene glycol, glucose, and electrolytes in a single pharmaceutical composition. This composite formulation addresses the contradiction by providing multiple simultaneous functions: tranexamic acid prevents adhesion formation through fibrin matrix stabilization, polyethylene glycol promotes gastrointestinal motility, glucose provides energy for cellular function, and electrolytes maintain fluid balance, thereby achieving both adhesion prevention and comprehensive gastrointestinal function restoration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively reduces the formation and severity of adhesions and ileus, leading to shorter hospital stays, reduced morbidity, and lower healthcare costs by enhancing gastrointestinal function and reducing complications.
Implementation Method 1
The initiation of an adhesion begins with the formation of a fibrin matrix, typically occurring from coagulation following trauma or inflammation. When two peritoneal surfaces are in close proximity following an injury, digestive enzymes work to degrade the fibrin matrix
Implementation Method 2
an aqueous pharmaceutical composition comprising tranexamic acid, polyethylene glycol, glucose, and at least one electrolyte
Data Source
Figure 1A~1B
Figure 2
Figure 3
AI summary
Disclosed herein are pharmaceutical compositions useful for the treatment and prevention of adhesions and ileus.